Guided Therapeutics (GTHP) Income towards Parent Company (2010 - 2025)
Guided Therapeutics (GTHP) reported Income towards Parent Company of -$1.2 million for Q4 2025, down 86.81% on a YoY basis from -$9.2 million in Q4 2024, and down 64.15% sequentially from -$742000.0 in Q3 2025.
Guided Therapeutics (GTHP) Income towards Parent Company (2010 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 16 years of Income towards Parent Company data on file, last reported at -$1.2 million in Q4 2025.
- For the quarter ending Q4 2025, Income towards Parent Company fell 86.81% year-over-year to -$1.2 million; the trailing twelve-month figure through Dec 2025 stood at -$3.2 million (down 32.31% YoY), and the FY2025 full-year result was -$3.2 million, down 32.23% from the prior year.
- Income towards Parent Company fell to -$1.2 million in Q4 2025, from -$742000.0 in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $68000.0 in Q3 2021 to a low of -$1.8 million in Q4 2022.
- A 5-year average of -$768650.0 and a median of -$693000.0 in 2023 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company surged 84.68% in 2021 and plunged 1720.59% in 2022, its largest moves.
- Tracing GTHP's Income towards Parent Company over 5 years: stood at -$444000.0 in 2021, then tumbled by 306.98% to -$1.8 million in 2022, then jumped by 78.64% to -$386000.0 in 2023, then tumbled by 68.91% to -$652000.0 in 2024, then sank by 86.81% to -$1.2 million in 2025.
- Business Quant data shows GTHP's Income towards Parent Company at -$1.2 million in Q4 2025, -$742000.0 in Q3 2025, and -$811000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn |
| 10 | Guided Therapeutics | 20.78 Mn | 20.72 Mn | 458,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.22 Mn |
| Sep 30, 2025 | -742,000.00 |
| Jun 30, 2025 | -811,000.00 |
| Mar 31, 2025 | -427,000.00 |
| Dec 31, 2024 | -652,000.00 |
| Sep 30, 2024 | -654,000.00 |
| Jun 30, 2024 | -709,000.00 |
| Mar 31, 2024 | -402,000.00 |
| Dec 31, 2023 | -386,000.00 |
| Sep 30, 2023 | -677,000.00 |
| Jun 30, 2023 | -1.56 Mn |
| Mar 31, 2023 | -869,000.00 |
| Dec 31, 2022 | -1.81 Mn |
| Sep 30, 2022 | -1.10 Mn |
| Jun 30, 2022 | -926,000.00 |
| Mar 31, 2022 | -507,000.00 |
| Dec 31, 2021 | -444,000.00 |
| Sep 30, 2021 | 68,000.00 |
| Jun 30, 2021 | -1.03 Mn |
| Mar 31, 2021 | -517,000.00 |